Justin Kim
Stock Analyst at Oppenheimer
(0.71)
# 3,540
Out of 5,176 analysts
39
Total ratings
33.33%
Success rate
-10.44%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Justin Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZURA Zura Bio | Maintains: Outperform | $16 → $15 | $5.62 | +166.90% | 3 | Mar 20, 2026 | |
| PHVS Pharvaris | Maintains: Outperform | $44 → $50 | $26.15 | +91.20% | 5 | Dec 4, 2025 | |
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $65 → $40 | $17.72 | +125.73% | 6 | Nov 6, 2024 | |
| CYTK Cytokinetics | Maintains: Outperform | $107 → $106 | $62.39 | +69.90% | 5 | May 9, 2024 | |
| IMCR Immunocore Holdings | Reiterates: Outperform | $85 → $87 | $30.28 | +187.32% | 5 | Feb 29, 2024 | |
| VERA Vera Therapeutics | Initiates: Outperform | $26 | $40.16 | -35.26% | 1 | Jan 25, 2024 | |
| ALDX Aldeyra Therapeutics | Downgrades: Perform | n/a | $1.85 | - | 2 | Oct 17, 2023 | |
| AUPH Aurinia Pharmaceuticals | Downgrades: Perform | n/a | $14.37 | - | 6 | Nov 4, 2022 | |
| BCRX BioCryst Pharmaceuticals | Downgrades: Perform | n/a | $9.40 | - | 5 | Aug 8, 2022 | |
| IONS Ionis Pharmaceuticals | Assumes: Outperform | $59 | $72.70 | -18.84% | 1 | Jul 18, 2022 |
Zura Bio
Mar 20, 2026
Maintains: Outperform
Price Target: $16 → $15
Current: $5.62
Upside: +166.90%
Pharvaris
Dec 4, 2025
Maintains: Outperform
Price Target: $44 → $50
Current: $26.15
Upside: +91.20%
Apellis Pharmaceuticals
Nov 6, 2024
Maintains: Outperform
Price Target: $65 → $40
Current: $17.72
Upside: +125.73%
Cytokinetics
May 9, 2024
Maintains: Outperform
Price Target: $107 → $106
Current: $62.39
Upside: +69.90%
Immunocore Holdings
Feb 29, 2024
Reiterates: Outperform
Price Target: $85 → $87
Current: $30.28
Upside: +187.32%
Vera Therapeutics
Jan 25, 2024
Initiates: Outperform
Price Target: $26
Current: $40.16
Upside: -35.26%
Aldeyra Therapeutics
Oct 17, 2023
Downgrades: Perform
Price Target: n/a
Current: $1.85
Upside: -
Aurinia Pharmaceuticals
Nov 4, 2022
Downgrades: Perform
Price Target: n/a
Current: $14.37
Upside: -
BioCryst Pharmaceuticals
Aug 8, 2022
Downgrades: Perform
Price Target: n/a
Current: $9.40
Upside: -
Ionis Pharmaceuticals
Jul 18, 2022
Assumes: Outperform
Price Target: $59
Current: $72.70
Upside: -18.84%